Literature DB >> 10218743

Importance of pH control in the management of GERD.

R H Hunt1.   

Abstract

The degree of esophageal mucosal injury that occurs in patients with gastroesophageal reflux disease depends on duration of exposure and pH of the refluxate. Evidence suggests that an intraesophageal pH of less than 4.0 directly correlates with the degree of mucosal injury. The advent of acid secretory inhibitors such as the histamine2-receptor antagonists (H2RAs) and, more recently, the proton pump inhibitors (PPIs) has revolutionized the treatment of patients with reflux disease. However, the evidence linking the degree of mucosal damage to pH of the refluxate has prompted investigators to reevaluate the effectiveness of these agents. The PPIs are significantly more effective than the H2RAs in achieving and sustaining an intragastric pH above 4.0. The results of clinical trials performed with the PPIs indicate a faster rate of healing of erosive esophagitis and of symptom relief than treatment with H2RAs.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10218743     DOI: 10.1001/archinte.159.7.649

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


  49 in total

1.  Intravenous esomeprazole.

Authors:  Gillian M Keating; David P Figgitt
Journal:  Drugs       Date:  2004       Impact factor: 9.546

2.  Transoral incisionless fundoplication 2.0 procedure using EsophyX™ for gastroesophageal reflux disease.

Authors:  Toshitaka Hoppo; Arul Immanuel; Matthew Schuchert; Zdenek Dubrava; Andrew Smith; Peter Nottle; David I Watson; Blair A Jobe
Journal:  J Gastrointest Surg       Date:  2010-09-28       Impact factor: 3.452

3.  Supplementation of Los Angeles classification with esophageal mucosa index of hemoglobin can predict the treatment response of erosive reflux esophagitis.

Authors:  Hsin Cheng; Yu-Ching Tsai; Wei-Ying Chen; Wei-Lun Chang; Hsiu-Chi Cheng; Bor-Shyang Sheu
Journal:  Surg Endosc       Date:  2011-02-07       Impact factor: 4.584

4.  Proton pump inhibitor monotherapy is effective to attenuate dyspepsia symptoms associated with gastroesophageal reflux disease: a multicenter prospective observational study.

Authors:  Kimio Isshi; Nobuyuki Matsuhashi; Takashi Joh; Kazuhide Higuchi; Katsuhiko Iwakiri; Takeshi Kamiya; Noriaki Manabe; Maiko Ogawa; Seiji Arihiro; Ken Haruma; Koji Nakada
Journal:  J Gastroenterol       Date:  2019-01-23       Impact factor: 7.527

Review 5.  Clinically significant drug interactions with antacids: an update.

Authors:  Ryuichi Ogawa; Hirotoshi Echizen
Journal:  Drugs       Date:  2011-10-01       Impact factor: 9.546

6.  Head-to-head comparison of H2-receptor antagonists and proton pump inhibitors in the treatment of erosive esophagitis: a meta-analysis.

Authors:  Wei-Hong Wang; Jia-Qing Huang; Ge-Fan Zheng; Harry Hua-Xiang Xia; Wai-Man Wong; Shiu-Kum Lam; Benjamin Chun-Yu Wong
Journal:  World J Gastroenterol       Date:  2005-07-14       Impact factor: 5.742

Review 7.  Histamine2-receptor antagonists: Rapid development of tachyphylaxis with repeat dosing.

Authors:  Johnson W McRorie; James A Kirby; Philip B Miner
Journal:  World J Gastrointest Pharmacol Ther       Date:  2014-05-06

8.  A pharmacokinetic study comparing single and repeated oral doses of 20 mg and 40 mg omeprazole and its two optical isomers, S-omeprazole (esomeprazole) and R-omeprazole, in healthy subjects.

Authors:  M Hassan-Alin; T Andersson; M Niazi; K Röhss
Journal:  Eur J Clin Pharmacol       Date:  2004-12-01       Impact factor: 2.953

9.  Essential role of pepsin in pathogenesis of acid reflux esophagitis in rats.

Authors:  Kenji Nagahama; Masanori Yamato; Hikaru Nishio; Koji Takeuchi
Journal:  Dig Dis Sci       Date:  2006-02       Impact factor: 3.199

Review 10.  Insights into the future of gastric acid suppression.

Authors:  Kenneth R DeVault; Nicholas J Talley
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2009-09       Impact factor: 46.802

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.